Randomised Evaluation of COVID-19 Therapy
RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia. The treatments being investigated are: COVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Casirivimab+Imdevimab, Tocilizumab, Aspirin, Baricitinib, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid or Anakinra (children only) Influenza: Baloxavir marboxil, Oseltamivir, Low-dose corticosteroids - Dexamethasone Community-acquired pneumonia: Low-dose corticosteroids - Dexamethasone
⁃ Patients are eligible for the study if all of the following are true:
⁃ (i) Hospitalised
⁃ (ii) Pneumonia syndrome
⁃ In general, pneumonia should be suspected when a patient presents with:
• typical symptoms of a new respiratory tract infection (e.g. influenza-like illness with fever and muscle pain, or respiratory illness with cough and shortness of breath); and
• objective evidence of acute lung disease (e.g. consolidation or ground-glass shadowing on X-ray or CT, hypoxia, or compatible clinical examination); and
• alternative causes have been considered unlikely or excluded (e.g. heart failure).
⁃ However, the diagnosis remains a clinical one based on the opinion of the managing doctor (the above criteria are just a guide).
⁃ (iii) One of the following diagnoses:
• Confirmed SARS-CoV-2 infection (including patients with influenza co-infection)
• Confirmed influenza A or B infection (including patients with SARS-CoV-2 co-infection)
• Community-acquired pneumonia with planned antibiotic treatment (excluding patients with suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis or Pneumocystis jirovecii pneumonia)